

ARRAY BIOPHARMA INC  
Form 8-K  
June 14, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 14, 2004**

**Array BioPharma Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-31979**  
(Commission  
File Number)

**84-1460811**  
(IRS Employer  
Identification No.)

**3200 Walnut Street, Boulder, Colorado**  
(Address of Principal Executive Offices)

**80301**  
(Zip Code)

Registrant's telephone number, including area code: **(303) 381-6600**

(Former Name or Former Address, if Changed Since Last Report)

---

**ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.**

On June 14, 2004, the Registrant issued a press release announcing the initiation of a Phase I clinical trial for its small molecule anticancer compound, ARRY-142886, the full text of which is attached hereto as Exhibit 99.1.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.**

(c)

Exhibits.

99.1

Press release dated June 14, 2004 entitled "Array BioPharma Achieves Milestone For Initiation of Phase I Clinical Trial For Anticancer Compound ARRY-142886."

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: June 14, 2004

By: /s/ ROBERT E. CONWAY

---

Robert E. Conway  
Chief Executive Officer

3

---

**EXHIBIT INDEX**

**Exhibit No.**

---

99.1 Press release dated June 14, 2004 entitled "Array BioPharma Achieves Milestone For Initiation of Phase I Clinical Trial For Anticancer Compound ARRY-142886."

---

QuickLinks

[ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.](#)

[ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)